Cleerly Raises $43M in Series B Funding
- Cleerly, a NYC-based company creating a new standard of care for heart disease, launched with $43m in Series B funding
- The round, which brings company’s total funding to $54m, was led by Vensana Capital
- As part of the financing, Justin Klein of Vensana Capital, Tripp Peake of LRVHealth and Vijay Lathi of New Leaf Venture Partners will join company’s Board of Directors
- The company intends to use the funds to scale its commercial reach, expand operational capabilities and strategic partnerships
- The company has launched its digital care pathway solution for heart attack prevention powered by proprietary AI and machine learning algorithms
- Its digital care pathway leverages non-invasive coronary computed tomography (CT) angiography to perform comprehensive coronary artery phenotyping
